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Targeting the epigenetic modifications of synovial cells
Abstract
Rheumatoid arthritis (RA) is a systemic inflammatory disease that mainly affects the synovial tissues of
joints. Like in other autoimmune-related disorders, both the etiology as well as the pathogenesis of RA
has not yet been completely unravelled. It is generally accepted, though, that autoimmune disorders
develop through a combination of the individual genetic susceptibility, environmental factors, and
dysregulated immune responses. Genetic predisposition has been described in RA, in particular as
“shared epitope”, a distinct sequence of amino acids within the antigen presenting peptide groove of the
major histocompatibility complex (MHC). Imbalanced immunity is reflected by the production of
autoantibodies and the accumulation of reactive helper T cells within the rheumatoid synovium. In
addition, environmental factors have been postulated as disease modulating agents, including smoking,
nutrition and infectious agents. So far, these factors have been studied almost exclusively as separate
agents. However, the way genes are transcribed can be affected by environment, nutrition, and ageing -
without changes in the nucleotide sequence of the underlying DNA. These patterns of alterations in the
gene expression profiles are called epigenetics. The term epigenetics is used to refer to molecular
processes that regulate gene expression patterns, however without changing the DNA nucleotide
sequence. These epigenetic changes comprise the postsynthetical methylation of DNA and
posttranscriptional modifications of histones, including methylation, phosphorylation, ubiquitination,
sumoylation, biotinlyation and, most importantly, deacetylation and acetylation. With respect to the
complex pathogenesis of rheumatic diseases, the epigenome is an emerging concept that integrates
different etiologies and, thus, offers the opportunity for novel therapeutic strategies. Based on the fact
that current therapies have not resulted in an ACR 70 above 60% and have never been targeting the
activated synovial fibroblast, novel therapeutic strategies should target the epigenetic pathways of
synovial activation in RA.
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SUMMARY 
Rheumatoid arthritis (RA) is a systemic inflammatory disease that mainly affects the synovial 
tissues of joints. Like in other autoimmune-related disorders, both the etiology as well as the 
pathogenesis of RA has not yet been completely unravelled. It is generally accepted, though, 
that autoimmune disorders develop through a combination of the individual genetic 
susceptibility, environmental factors, and dysregulated immune responses.  
Genetic predisposition has been described in RA, in particular as “shared epitope”, a distinct 
sequence of amino acids within the antigen presenting peptide groove of the major 
histocompatibility complex (MHC). Imbalanced immunity is reflected by the production of 
autoantibodies and the accumulation of reactive helper T cells within the rheumatoid 
synovium. In addition, environmental factors have been postulated as disease modulating 
agents, including smoking, nutrition and infectious agents. So far, these factors have been 
studied almost exclusively as separate agents.  
 
 However, the way genes are transcribed can be affected by environment, nutrition, and 
ageing – without changes in the nucleotide sequence of the underlying DNA. These patterns 
of alterations in the gene expression profiles are called epigenetics. The term epigenetics is 
used to refer to molecular processes that regulate gene expression patterns, however without 
changing the DNA nucleotide sequence. These epigenetic changes comprise the 
postsynthetical methylation of DNA and posttranscriptional modifications of histones, 
including methylation, phosphorylation, ubiquitination, sumoylation, biotinlyation and, most 
importantly, deacetylation and acetylation. With respect to the complex pathogenesis of 
rheumatic diseases, the epigenome is an emerging concept that integrates different etiologies 
and, thus, offers the opportunity for novel therapeutic strategies. Based on the fact that current 
therapies have not resulted in an ACR 70 above 60% and have never been targeting the 
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activated synovial fibroblast, novel therapeutic strategies should target the epigenetic 
pathways of synovial activation in RA.   
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1. INTRODUCTION 
Less than a decade ago, the number of genes that is encoded within the nucleus of a single 
human cell was estimated to at least 100’000 genes or more. Much hope for our 
understanding of pathogenesis and treatment of diseases thus was put on the successful 
accomplishment of the human genome project. It was therefore most surprising that the 
number of genes finally detected was quite low.  Most of the 25000 genes identified encode 
biological functions that remain undiscovered so far and the functional characterization of 
these genes in normal physiology as well as in the pathogenesis of diseases remains the main 
issue for biomedical research in the next years [1]. However, this approach through 
“functional genomics” might be biased by postreplicational, posttranscriptional as well as 
posttranslational modifications – and proteome diversity due to alternative splicing of mRNA 
transcripts and other biochemical alterations somehow limits the utility of genomic 
information [2, 3]. The question how the genome integrates intrinsic and environmental 
factors thus might be answered by the emerging concept of the epigenotype. The term 
epigenetics comprises stable alterations of the genetic information that are heritable but do not 
involve mutations of the DNA sequence itself. Epigenetic regulations are mediated by several 
biochemical phenomenona, most importantly however by histone modifications and DNA 
methylation. Epimutations and epigenetics are required for development and differentiation of 
cells within a multicellular organism. Moreover, they allow a cell to respond to environmental 
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stimuli throughout adult life by means of stable expression or repression of genes in specific 
cell types. Currently, no epigenetic information is systematically analysed and epigenetic 
modifications have not been assessed within the human genome project. Since epigenetics 
might play the linking role between environmental factors and genetics in determining a 
certain phenotype, the investigation of epigenetic alterations along the lines of chromosome-
wide and promoter specific arrays will represent an fascinating area of future research. 
Already, pilot studies for the human epigenome project have been undertaken [4]. In this 
regard, the epigenome could provide a readout of an individual’s environmental history [5] 
and the convential method of studying human diseases by molecular genetic approaches and 
additional environmental factors could soon be extended to a novel field of epigenetic 
epidemiology. 
Within this chapter, we focus on the emerging concept of epigenetics and its implications for 
potential treatment strategies in rheumatoid arthritis (RA). 
 
2. DEFINITIONS 
The term epigenetics is used to refer to molecular processes that regulate gene expression 
patterns, however without changing the DNA nucleotide sequence. The epigenome of a cell is 
defined by two major groups of biochemical alterations: postsynthetic methylation of DNA 
and modifications of histones that package DNA and, thus, modulate the accessibility for 
transcription factors to information present on nucleid acid . These modifications are 
mitotically heritable and can be transmitted during cell division from one generation of cells 
to the next. Both physiological and pathological responses to environmental stimuli are 
probably mediated by epigenetic mechanisms. Even in the absence of such environmental 
factors, the epigenomic profile is reversible and highly variable, probably due to stochastic 
events in the somatic inheritance of epigenetic profiles [6]. The remarkable degree of 
variation distinguishes epimutations and epigenetic changes from “true” genetic mutations. 
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From a therapeutic view, finally, the reversibility of epigenetic changes offers the opportunity 
of using pharmacological strategies to revolve a certain phenotype [7]. The dynamic 
interaction between all factors involved is illustrated in Figure 1. 
 
Insert Figure 1  
 
2.1. DNA METHYLATION [8] 
DNA methylation in eukaryotes is a post-replication modification restricted to the pyrimidine 
base cytosine within the dinucelotide sequence CpG, , which form clusters of genetic 
regions (CpG islands) that surround the promoter region of protein-coding genes. 
Phenotypic analyses of several DNA methyltransferase (DNMT) enzymes have revealed 
interesting mechanistic insights into epigenetic methylation: DNMT3a and 3b for example are 
de novo methyltransferases and introduce cytosine methylation at CpG sites that were 
previously unmethylated. DNMT1 acts during replication and cell division by copying 
existing methyltransferase pattern onto newly synthesized DNA strands. For the process of 
DNA methylation, DNMTs use S-adenosylmethionine as a methyl donor, whose generation 
is mainly modulated by the availability of different methyl donors. Briefly, 
methyltetrahydrofolate governs the conversion of homocysteine to methionine, which is 
further metabolized to S-adenosylmethionine. Deficiencies in the enzymes involved in these 
processes result in hypomethylation of DNA. Several nutrients play key roles within this 
metabolism. The major dietary sources of methyl groups include folate, choline and 
vitamin B12 [9-12]. 
The insertion of a methyl group at position five of the cytosine ring leads to structural changes 
of chromatin and is associated with gene repression. This silencing function on the level of 
 5
gene expression can be achieved by different mechanisms. Structural modifications of the 
DNA might block the proper docking of DNA-binding factors to their fitting recognition sites, 
thus inhibiting gene transcription, whereas Methyl-CpG-binding proteins (MBPs, such as 
MeCP2, MBD1-4) function redundantly as transcriptional co-repressors. Moreover, MBPs 
have been shown to interact with enzymes regulating histone modifications. This interaction 
could provide a link between different epigenetic mechanisms. 
 
2.2. HISTONE MODIFICATIONS [13, 14] 
Apart from DNA methylation, local chromatin architecture and, thus, transcriptional 
regulation of gene expression is strongly influenced by covalent biochemical modifications 
subsumed under the term histone code. These epigenetic changes include 
posttranscriptional modifications of histones, including methylation, phosphorylation, 
ubiquitination, sumoylation, biotinlyation and, most importantly, deacetylation and 
acetylation [14, 15]. Nucleosomes are the fundamental building blocks of the heterochromatin 
consisting of an octamer of four core histones and DNA. This octameric structure is made out 
of a H3-H4 tetramer and two H2A-H2B dimers. Histone H1 has a linker function between 
DNA and protein and governs the path of the DNA as it exits from the nucleosome. With 
respect to histone modification, the DNA of physiologically resting cells is wrapped tightly 
around the core histones, thus preventing the binding of basal transcription factors (e.g. the 
TATA box binding protein) and RNA polymerase II [16]. Gene transcription is initiated when 
histones are modified in order to create an open, accessible form of chromatin. Probably the 
most investigated modification of the histone code is the (de)acetylation of core histones. 
Histone acetylation is performed by histone acetyltransferases (short: histone acetylases, 
HATs) that neutralize positive charges at the  amino groups of lysine residues at the N-
termini. Hyperacetylation of histones is generally associated with enhanced rates of gene 
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transcription. Conversely, the space between histones and surrounding DNA is reduced by de- 
and hypoacetylation – and transcription factors are sterically hindered of binding, leading to 
gene silencing. Taken together, the gene transcription rate is regulated by the balance between 
histone acetylation and histone deacetylation. The targeted deacetylation of histones is 
performed by several multisubunit enzyme complexes, i.e. histone deacetylases (HDACs) [15, 
17]. Figures 2 shows the dynamic interplay of epigenetic mechanisms between states of silent 
and transcriptionally active chromatin. 
 
Insert Figure 2 
 
Eukaryotic members of the HDAC family can be divided into three major groups, of which 
class I and class II HDACs so far comprise the best characterized classes with respect to 
function. The class I comprises HDAC1, 2, 3, and HDAC 8 and localize almost exclusively 
within the nucleus to exert their function. HDACs 4, 5, 6, 7, 9, and 10 are subsumed under the 
term class II HDACs, which are mainly found in the cytoplasm and are shuttled into the 
nucleus when needed. Whereas class I HDACs are expressed in most cell types, the 
expression pattern of class II HDACs appears to be tissue-specific, indicating a possible role 
in cellular differentiation and development. HDACs remove the acetyl group from the 
nucleosomal core histones by using a sophisticated charge-relay system using Zn2+-ions as 
prosthetic group. HDAC inhibitors such as Trichostatin A (TSA) fit into the active catalytic 
pocket of the enzyme, exchange the zinc ion and, thus, make the system dysfunctional [18].  
 
HATs, on the other hand, comprise a family of proteins that catalyze the acetylation of lysine 
residues of one of the core histone proteins [19]. Traditionally, HATs are categorized in two 
groups based on there subcellular localization: type A, located in the nucleus and type B, 
located in the cytoplasm. Nuclear type A-HATs acetylate nucleosomal histones within 
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chromatin in the nucleus and thus type A HATs are related to transcriptional regulation 
processes. On the other hand, type B HATs acetylate newly synthesized free histones in the 
cytoplasm. Since recent data indicate that HAT activity can be induced also in multiple 
protein complexes that are related to transcriptional processes, this historically categorization 
is no longer used. Amino acid sequence analyses of all HAT proteins revealed the important 
feature that HAT proteins fall into distinct families that share relatively poor sequence 
similarity. All three superfamilies (GNAT, MYST and p300/CBP-HATs) however have a 
highly conserved acetyl-CoA binding site in common.  
The best-understood family of HATs is the GNAT (general control nonderepressilble -5 
(Gcn5)-related N-acetyltransferase) superfamily. Humans express two (Gcn5)-like 
acetyltransferases: Gcn5 and PCAF (p300/CBP associated factor). Both of these proteins can 
interact with an other HAT protein complex, i.e. p300/CBP. P300/CBP is a ubiquitously 
expressed, global transcriptional co-activator that regulates cell cycle, differentiation and 
apoptosis. The HAT activities of p300/CBP enables the transactivation of DNA binding 
transcription factors (p53, E2F, myb, GATA1, Rb) as well as the acetylation of all 4 histone 
proteins. Mutations in the HAT active site inhibit their transcriptional activating function. 
The MYST family of HATs is particularly interesting as these proteins show similarity with 
other acetyltransferases exclusively within the acetyl-coenzyme A binding motif. The 
members of the MYST family named this HAT group: MOZ (monocytic leukemia zinc finger 
protein), Ybf2/sas3, Sas2, and Tip60. MOZ is involved in the chromosome translocations 
associated with acute myeloid leukemia. MOZ acts as a transcriptional coactivator for AML1, 
which is essential for establishment of definitive hematopoiesis. An overview of the different 
HAT families is provided in Table 1. 
 
Insert Table 1 
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Finally, DNA methylation and histone modifications have been considered as two distinct 
mechanisms, which influence the level of gene expression in an independent manner. It was 
shown however that HDACs are correlated to DNA methylation, either through direct 
interaction of HDACS with DNMTs or by the function of Methyl-CpG-binding proteins 
(MBPs). Another line of evidence suggesting that MBPs interact with HDAC1 and HDAC2 to 
recruit the Sin3 corepressor protein further supports a link between DNA methylation and 
histone modifications [20, 21]. Thus, DNMTs appear to be some kind of dual function 
proteins, which are recruited by transcriptional repressors. On the other hand, they have a 
non-enzymatic function interacting with histone methyltransferases and HDACs, hence 
leading to chromatin remodelling [22, 23]. 
 
3. EPIGENETIC MODIFICATIONS in RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a systemic disease mainly affecting the synovial tissues of joints. 
The process of ongoing inflammation and erosion of articular cartilage and subchondral bone 
causes severe pain, functional impairment and ultimately disability [24]. Like in other 
autoimmune-related disorders, both the etiology as well as the pathogenesis of RA has not yet 
been completely unravelled. It is generally accepted, though, that autoimmune disorders 
develop through a combination of the individual genetic susceptibility, environmental factors, 
and dysregulated immune responses [25, 26]. 
Genetic predisposition has been described in RA, in particular as “shared epitope”, a distinct 
sequence of amino acids within the antigen presenting peptide groove of the major 
histocompatibility complex (MHC). Imbalanced immunity is reflected by the production of 
autoantibodies such as rheumatoid factors and cyclic citrullinated peptides as well as by the 
accumulation of reactive helper T cells within the rheumatoid synovium. In addition, 
environmental factors have been postulated as disease modulating agents, including smoking, 
nutrition and infectious agents. So far, these factors have been studied almost exclusively as 
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separate disease driving agents. As mentioned before, however, the way genes are transcribed 
can be affected by environment, nutrition, and ageing that influence the epigenetic patterns. 
In this regard, Kim and coworkers investigated whether methotrexate induces genomic DNA 
hypomethylation in patients with inflammatory arthritis [27]. Methotrexate is an 
immunosuppressive agent, which is used in the treatment of RA in addition to 
glucocorticosteroids and biologicals. Methotrexate exerts its function by blocking the enzyme 
dihydrofolat reductase thus interrupting the methyl transfer function of folate. Within the 
study in question, the amount of methylated genomic DNA was lowest in subjects with 
inflammatory arthritis who were not taking methotrexate, highest in subjects with 
inflammatory arthritis who were taking methotrexate, and intermediate in control subjects. 
Surprisingly, these data indicate that inflammatory arthritis might be associated with genomic 
DNA hypomethylation, which can be reversed with methotrexate [27]. Since methotrexate 
would be expected to inhibit transmethylation, the results from this study are somewhat 
paradoxical.  
In an animal model of adjuvant arthritis, treatment with the combination of tryptophan, 
methionine and methotrexate caused a drastically reduced course of arthritis, whereas 
treatment with methotrexate alone exerted only a slight inhibitory effect [28]. The methyl 
groups transferred during methylation of DNA are ultimately derived from methionine. 
Therefore, high methionine intake was suggested to increase DNA methylation. Because of 
the distinct biochemistry within the methionine cycle, methylation of DNA probably is 
impaired under dietary excess of methionine by inhibiting remethylation of homocysteine [29].  
Mature B-lymphocytes and plasma cells express CD21 (complement receptor II) on the cell  
surface to exert their function as (auto-)antibody producing cells. CD21 binds the complement 
component C3d, which is expressed within immune complexes. Interestingly, immature 
precursor of B cells, such as pro-, pre-, or plasma B lymphocytes do not express CD21, 
probably because they contain a methylated CpG island within its promoter region. When 
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peripheral blood mononuclear cells and synovial fluid mononuclear cells from patients with 
RA were investigated, however, the CD21-CpG island was found to be demethylated [30]. 
These data suggest a role of these cells in the dysregulation of the immune response in RA 
patients.  
It is of interest to note here that most therapies have been targeting T- and B-lymphocytes 
and/ or monocytes/ macrophages and their respective proinflammatory cytokines, but never 
the synovial fibroblast, which was shown to be activated even in the absence of stimulating 
immune cells and cytokines [31]. This observation has prompted us to study signaling 
pathways in RA-SF. Since DNA methylation is also involved in the regulation of endogenous 
retroviral sequences, which have been suggested to play a role in the induction of autoimmune 
diseases, we searched for the presence of such sequences. By screening RA synovial fluid 
pellets, a homologue to the human retrotransposable L1 element was found by our group [32]. 
Human L1s (or LINE-1, long interspersed nuclear elements) are poly(A)-retrotransposons 
lacking long terminal repeats. L1s contain an untranslated region (UTR) and two open reading 
frames (ORF1 and 2), the latter one encoding for a protein with endonuclease and reverse 
transcriptase activity. Inhibition of the DNA methyltransfer by 5-aza-2’-deoxycytidine 
induced the expression of L1s by DNA hypomethylation. It was further shown that three of 
five CpG islands of the genomic L1 5'-UTR were hypomethylated in RA synovial fibroblasts. 
Moreover, L1 retroelements induced the expression of p38, one of the four isoforms of 
mitogen-activated protein kinases as well as galectin-3 binding proteins [32, 33]. 
With respect to histone acetylation, Ito and coworkers could show that reduced activity of 
HDAC class I enzymes leads to enhanced transcription of genes encoding inflammatory 
proteins, such as tumor necrosis factor (TNF)-,  interleukin (IL)-8 and matrix 
metalloproteinase (MMP)-9 [34]. These studies were performed in lung tissue derived from 
patients with inflammatory and obstructive pneumopathies such as asthma bronchiale and 
chronic obstructive pulmonary disease (COPD). Our laboratory has investigated HDAC 
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activity levels in total synovial tissue of patients with RA [35]. When we compared these 
samples with the respective levels in patients with osteoarthritis and normal synovial tissue, 
we found a significant decrease of total HDAC activity. This was probably due to reduced 
expression of HDAC 1 and 2 proteins in synovial tissue. Conversely, several studies have 
proposed HDAC inhibitors as beneficial agents for the treatment of RA and other 
inflammatory processes [36, 37].  
It remains unclear, whether the observed reduction in HDAC activity is “the chicken or the 
egg” in the pathogenesis of RA and it can not be excluded that the reduced HDAC activity 
levels reflect an epiphenomenon of ongoing inflammation [35]. Evidence for a key role of 
histone modifications is based on the fact that the pro-inflammatory transcription factor 
nuclear factor kappa B (NFB) is highly activated in RA synovial cells (for review see [24]). 
Since Ito et al have further shown that HDAC 2 suppresses the NFB-mediated gene 
expression [38], we speculate that class I HDACs appear to act upstream of NFB and other 
related transcription factors in RA. Thus, HDAC activity appears to play a key role in the 
pathogenesis of autoimmune-related joint diseases. 
Jungel and coworkers finally have shown that co-treatment of RA-SFs with the HDAC 
inhibitor TSA and TNF-related apoptosis inducing ligand (TRAIL) induced programmed cell 
death (apoptosis) in a synergistic manner. When used alone, TRAIL and TSA exhibited no or 
only a modest effect [39].  
Regulatory T cells (Tregs) have been thought to be of potential benefit for the treatment of 
autoimmune diseases and Foxp3 has been proposed as a master regulator governing both 
development and function of CD4-positive T lymphocytes. In this regard, it was recently 
shown that the expression of Foxp3 has to be stabilized by complete demethylation of CpG 
islands within this promoter region in order to develop a permanent suppressor cell lineage. 
These findings might be of clinical importance with respect to the therapeutical transfer of T 
regs in autoimmune diseases [40].  
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Taken the data on epigenetic modifications on RA-SF together with the fact that all current 
therapies, including the novel biologics, do not result in an ACR 70 greater than 60%, and that 
the RA-SF has never been targeted by any therapeutic strategy, future efforts should be given 
to target the activated RA-SF [41]. 
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4. PERSPECTIVES 
The current method of investigating the pathogenesis of diseases includes molecular genetic 
analyses to identify disease-specific gene sequences on one side and epidemiological 
approaches to detect potential environmental factors on the other hand. These efforts have 
only been partly successful to find explanations for the complex pathogenesis of autoimmune-
related diseases such as RA. Epigenetic modifications thus appear to play pathogenetic key 
roles in genetically predisposed individuals. Distinct from genetic mutations, which are 
permanent, epigenetic alterations show an intrinsic plasticity and might well be targeted by 
pharmacological strategies. Various drugs that modulate the epigenetic reactions in rheumatic 
arthritis have already been tested in vitro and in animal models. In particular, targeting DNA 
methylation and histone acetylation are clearly within future therapeutic prospects. Several 
epigenetic drugs have also been approved by the FDA, in particular for clinical trials 
addressing the treatment of malignancies (reviewed in [42]). Nucleoside analogues such as 
azacytidine as well as the first orally bioavailable inhibitor zebularine inhibit DNA 
methylation by being incorporated into replicating DNA. These agents have been tested 
successfully in the treatment of hematologic cancers and myelodysplastic syndromes. Another 
group of DNA methylation inhibitors includes non-nucleoside analogues that inhibit DNA 
methyltransferase enzyme activity in order to exert their function. These drugs are already in 
clinical use and comprise the anesthetic agent procaine, procainamide (an antiarrhythmic 
compound) and the antihypertensive drug hydralazine. It has been reported that these agents 
cause global DNA hympomethylation in cancer cells as well as T lymphocytes in different 
experimental systems. On the other hand, various HDAC inhibitors are currently in phase I/ II 
of clinical trials. These inhibitors include TSA, suberoylanilide hydroxamic acid (SAHA), 
valproic acid, phenylbutyrate and others. SAHA, for example, was accepted by the FDA only 
recently for the treatment of advanced cutaneous T-cell lymphoma. Other studies have 
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revealed strong anticancer activities of HDAC inhibitors and feasible pharmacokinetic 
properties for the treatment of hematologic tumors. However, it is important to stress that all 
inhibitors, which are currently used, block the different HDAC enzymes without any 
preference for specific isoforms. To provide a more specific approach for future therapies, 
novel compounds have to be developed.  
In addition, the combination of agents that block both DNA methylation and histone 
modifications might be of therapeutical interest. TSA, which has long been considered as a 
specific histone deacetylase inhibitor leading to histone hyperacetylation and activation of 
unmethylated gene sequences, has been shown to induce systemic and replication-
independent demethylation of DNA [43] . The results from this study should be taken into 
account when novel, TSA-related epigenetic drugs are designed.  
Finally, dietary recommendations for putative epigenetic drugs as found in green tea, garlic, 
broccoli and other phytochemical compounds [44, 45] might be an additional option apart 
from pharmaceutical interventions.  
Until then, however, novel biologicals that reverse the epigenetic pattern have to be designed. 
Moreover, hurdles facing in vivo efficacy and toxic side effects have to be overcome. Along 
the line of chromosome-wide and promoter specific arrays, the epigenotype has to be 
investigated, especially with respect to the activated RA-SF. This will open the scope for 
future therapies and might push epigenetic inhibitors as potent agents to treat or prevent 
disease on an individual basis. 
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6. FIGURE LEGENDS 
 
Figure 1 
Interaction between genes (genom), epigenetics (epigenom) and phenotype (adapted and 
modified after [46]). Postsynthetical modifications of DNA are inherited (as epimutations) or 
establish during development and cell differentiation. Physiological and pathological 
responses to environmental stimuli (such as nutrition, age, and infections) are also governed 
by epigenetic mechanisms. Even in the absence of such environmental factors, the 
epigenomic profile is reversible and highly variable, probably due to stochastic events in the 
somatic inheritance and in maintenance of epigenetic profiles.  
 
Figure 2 
The dynamic balance between silent and transcriptionally active chromatin (modified after 
[23]). Histone deacetylases (HDACs), DNA methyltransferases (DNMTs) and Methyl-CpG-
binding proteins (MBPs) provide gene repression, whereas transcription factors (TFs), histone 
acetyltransferases (HATs) and HDAC inhibitors (HDACi) lead to enhanced gene transcription 
rates. Disturbances and changes in one or more of these components shift the balance to any 
side of gene expression.                                                                                                                                         
 
 
Table 1 
Histone acetyltransferase (HAT) superfamily (modified after [47]). 
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DNMTs MBPs HDACs
TFs HDACi HATs
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